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Abstract
Exercise intolerance due to impaired oxidative metabolism is a prominent symptom in patients with mitochondrial myopathy
(MM), but it is still uncertain whether L-carnitine supplementation is beneficial for patients with MM. The aim of our study was to
investigate the effects of L-carnitine on exercise performance in MM. Twelve MM subjects (mean age±SD=35.4±10.8 years)
with chronic progressive external ophthalmoplegia (CPEO) were first compared to 10 healthy controls (mean
age±SD=29±7.8 years) before they were randomly assigned to receive L-carnitine supplementation (3 g/daily) or placebo
in a double-blind crossover design. Clinical status, body composition, respiratory function tests, peripheral muscle strength
(isokinetic and isometric torque) and cardiopulmonary exercise tests (incremental to peak exercise and at 70% of maximal),
constant work rate (CWR) exercise test, to the limit of tolerance [Tlim]) were assessed after 2 months of L-carnitine/placebo
administration. Patients with MM presented with lower mean height, total body weight, fat-free mass, and peripheral muscle
strength compared to controls in the pre-test evaluation. After L-carnitine supplementation, the patients with MM significantly
improved their Tlim (14±1.9 vs 11±1.4 min) and oxygen consumption (
:
VO2) at CWR exercise, both at isotime (1151±115 vs
1049±104 mL/min) and at Tlim (1223±114 vs 1060±108 mL/min). These results indicate that L-carnitine supple-
mentation may improve aerobic capacity and exercise tolerance during high-intensity CWRs in MM patients with CPEO.
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Introduction
Mitochondrial diseases caused by mutations in
nuclear and mitochondrial DNA (mtDNA) are recognized
as the most common types of inherited neuromuscular
diseases. These genetic defects in oxidative phosphor-
ylation lead to specific abnormalities in exercise perfor-
mance, such as a reduced maximal whole-body oxygen
consumption and elevated lactate levels during exercise
(1,2).
Exercise intolerance, particularly in the form of chronic
progressive external ophthalmoplegia (CPEO), is a very
common symptom in individuals with mitochondrial myo-
pathy (MM) and is typically associated with undue fatigue
at relatively low exertion levels (3). The most prominent
symptoms come from skeletal muscle, due to their lower
oxidative capacity and significant levels of mutant mtDNA
compared with other tissues. Impaired oxidative phos-
phorylation may result in exercise intolerance breath-
lessness, exaggerated lactic acidosis, and low exercise
capacity (4). This effect may augment the patient’s
functional limitations and lead to a vicious cycle of
exercise intolerance exacerbation (4).
Although there is no specific therapy for MM (5,6), L-
carnitine, an amine administered as a dietary supplement,
has been reported to increase the influx of fatty acids into
the mitochondria, facilitating pyruvate oxidation and
reducing lactate synthesis (7). There is currently no
available disease-modifying therapy for MM. Several
agents, mostly nutritional supplements, including L-
carnitine, have been investigated with double-blind,
placebo-controlled studies, but none has demonstrated
effects in clinical disease end-points, although numerous
non-blind studies and case reports have suggested that it
is beneficial (8).
Thus, the purpose of the present study was to
determine whether L-carnitine can improve exercise
tolerance in MM subjects. The central hypothesis was
that the supplement would induce physiological changes
by increasing oxidative metabolism, resulting in beneficial
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effects on skeletal muscle performance and exercise
tolerance in these patients.
Material and Methods
Twelve patients with biopsy-proven MM followed at
the Neuromuscular Division of the Escola Paulista de
Medicina at the Universidade Federal de Sa˜o Paulo
(Unifesp) agreed to participate in the study. Patients were
diagnosed after clinical and biopsy evaluation. The
muscle biopsy was obtained from the right vastus lateralis
at least 3 months before the beginning of the study
protocol. Samples were frozen in isopentane cooled by
liquid nitrogen for histological and histocytochemical
analysis. All muscle biopsies exhibited abnormal mito-
chondrial proliferation as ragged red fibers under modified
Gomori trichrome stain and succinate dehydrogenase
staining, and as cytochrome c oxidase-deficient or
negative fibers, as well as mosaic patterns dominated
by type 1 fibers (8,9).
The inclusion criteria for the trial were: i) MM with
CPEO; ii) age .14 years; and iii) complaint of exercise
intolerance, mild fixed limb weakness, or myalgias. The
exclusion criteria were: i) cardiac pacemaker; ii) severe
limb weakness; iii) concomitant ergogenic supplementa-
tion treatment; iv) renal, cardiac, or pulmonary dysfunc-
tion; or v) participation in regular physical activity in the
preceding year.
Written informed consent was obtained from all
patients, and the study protocol was approved by the
Ethics Committee of the Universidade Federal de Sa˜o
Paulo (#0943/03).
Ten age- and gender-matched healthy volunteers
constituted the control group. To match the habitual
physical activities of the patients, controls were required
to have very low daily physical activity scores as
determined by the Baecke questionnaire (a total score
of ,6) (10).
Study protocol
The study protocol for MM patients followed a double-
blind placebo/L-carnitine controlled crossover design.
Before entering the study, all patients were evaluated for
compliance of the proposed tests (pre-test evaluation).
Control subjects did not receive any supplementary
intervention and were only evaluated at the beginning of
the study with the same tests, excluding the constant work
rate (CWR) exercise test (Figure 1). For the double-blind
trial, enrolled patients were randomly assigned to receive
either 3 g L-carnitine or 3 g placebo in one daily dose (with
breakfast or lunch) for 8 weeks. They took identical-looking
capsules (DrogaDerma, Brazil). The second evaluation
was performed 8 weeks after the patients had received
either L-carnitine or placebo. After that, a 4-week washout
period was carried out to minimize the drug effect and the
third evaluation was performed after L-carnitine/placebo
crossover (Figure 1). Most studies that administered L-
carnitine to patients with chronic diseases utilized daily
doses between 2 and 4 g (11,12). The 3-g dose given in
this study has been used empirically in the Neuromuscular
Division of the Escola Paulista de Medicina, Unifesp.
Treatment adherence was confirmed by the patient
during weekly phone calls and monthly appointments at
the outpatient respiratory clinic. In these consultations,
patients were asked to bring their empty bottles of L-
carnitine and receive a new monthly supplement supply.
They also reported possible side effects attributed to the
supplement or placebo. The patients had 100% compli-
ance with the protocol, and no patient dropped out during
the study.
Measurements
Body composition. The patient’s mid-arm circum-
ference was measured, and the skin fold thicknesses at
the bicipital and tricipital levels were obtained using a
skin-fold caliper. The arm muscle circumference (cm) was
derived from these readings. Bioelectrical impedance
(Quantum BIA-101Q, RJL-101TM, USA) was used to
estimate the total body fat-free mass (FFM, kg). The
FFM index (FFMI) was calculated as the ratio of the
patient’s FFM to his or her height (m2).
Pulmonary function testing. Spirometry lung volumes
and maximal voluntary ventilation (MVV) were obtained in
all subjects (Elite series, Medical Graphics Co. [MGC],
USA). Data are reported as a percentage of the predicted
values obtained in healthy Brazilian subjects (13-15).
Cardiopulmonary exercise testing (CPET). Incre-
mental cardiopulmonary exercise tests (ICPET) were
performed using an electromagnetically braked cycle
ergometer (CPE 2000, MGC). The gas exchange,
ventilator and cardiovascular variables were analyzed
breath-by-breath (CardiO2 System, MGC) during an
ICPET following a linear ‘‘ramp’’ pattern of increase
(16): 5-15 W/min and 15-25 W/min in patients and
healthy subjects, respectively. This protocol was
designed such that the test time was more than 8 min
and less than 12 min, based on ‘‘symptom-limited
interruption’’ for all the participants. The following
variables were reported as 15-s means: oxygen uptake
(
:
VO2 in mL/min), carbon dioxide output (
:
VCO2 in mL/
min), minute ventilation (
:
VE in L/min), and the end-tidal
partial pressures of oxygen and carbon dioxide (PETO2
and PETCO2, mmHg). Subject heart rate (HR, bpm) was
automatically calculated from the R-R distance obtained
with 12-lead electrocardiogram tracing (CardiO2 System,
MGC). The
:
VO2 at the estimated lactate threshold was
evaluated using the gas-exchange threshold (GET) (17).
The average
:
VO2 in the last 15 s of exercise was
considered representative of the subject’s peak
:
VO2
(18). On a different day, patients also underwent a CWR
exercise test on a cycle ergometer with a load
corresponding to 70% of that obtained in the peak
L-carnitine in mitochondrial myopathy 355
www.bjournal.com.br Braz J Med Biol Res 48(4) 2015
exercise to their limit of tolerance (Tlim).
Blood lactate. Blood samples from the earlobe were
collected at peak of the ICPET and in the 5th min of the
recovery period after L-carnitine or placebo treatment.
These samples were analyzed on a lactimeter YSI model
1500 Sport (Yellow Springs Inc., USA) using an electro-
enzymatic method.
Peripheral muscle testing. The isokinetic muscle
endurance of the dominant knee extensor (quadriceps)
was measured using a computer-based dynamometer
(Contrex CE, Switzerland). The subject was seated
upright on the dynamometer chair, with his or her back
fully supported. The lever arm’s mechanical axis of
rotation was aligned with the knee’s axis of rotation.
Muscle strength (a concentric evaluation of the knee’s
flexion and extension movements) was determined from
the peak torque (PT) measured during five consecutive
maximal repetitions at an angular velocity at 606/s.
Isometric torque (IT) was evaluated from the maximal
knee strength sustained for 5 s at 606. The endurance of
the quadriceps was determined as the total work (TW)
achieved during 20 consecutive maximal repetitions at an
angular velocity of 3006/s (19).
Statistical analysis
Statistical analysis was performed using SPSS 15.0
for Windows (USA). To compare data from controls with
the placebo data of patients, we utilized t-tests for
independent samples, and the results are reported as
means and standard deviations. For comparison of the
effect of placebo and L-carnitine in the patient group, a
crossover trial was performed using a generalized linear
mixed model (GLM) design based on repeated measures
to account for treatment and carry-over effects
(placeboRL-carnitine vs L-carnitineRplacebo) (Figure
1). For this analysis, we performed Mauchly’s test of
sphericity, and when this was not met, we applied the
Huynh correction (20). In case of no influence of the
intervention sequence, the randomized patients were
analyzed as a single group (n=12).
Results
During pre-test assessment, patients with MM were
found to have lower weight, height, body mass index and
FFMI, compared to normal subjects (P,0.05, Table 1).
The residual volume (RV; % predicted) was significantly
increased, and the MVV (% predicted) was significantly
lower in patients compared to controls. Patients also
presented significantly lower peak torque, isometric
torque, and total work (Table 2).
We also observed that peak
:
VO2 (in mL/min and as a
% predicted), peak work rate, and GET were significantly
lower in patients compared to controls (Table 3). At peak
exercise, patients with MM predominantly reported leg
fatigue as evaluated by the Borg scale for lower limbs
(Table 3).
No anthropometric or peripheral muscle test differ-
ences were observed after L-carnitine supplementation,
compared to patients who received placebo (Table 4).
Furthermore, MM subjects maintained the same body
mass index, FFM, FFMI, and arm muscle circumference.
Figure 1. Design of study protocol. MM:
mitochondrial myopathy; ICPET: incremental
cardiopulmonary exercise test; CWR: constant
work rate.
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However, we did find a significant improvement in
inspiratory capacity, both in absolute and % predicted,
after L-carnitine supplementation.
With regard to the ICPET, no significant differences of
metabolic, ventilator, or cardiovascular variables were
detected comparing the studied interventions in the
patient group (Table 5). In contrast, during CWR
symptom-limited exercise testing (Table 6), we observed
a significantly longer Tlim, higher
:
VO2 at the 6th min of
exercise (isotime) and at Tlim after L-carnitine supple-
mentation compared to the placebo. We also observed a
significantly higher oxygen pulse (
:
VO2/HR, mL/beat)
value at Tlim after L-carnitine compared to placebo.
Importantly, at isotime, the gas-exchange ratio was lower
after L-carnitine compared to placebo.
Discussion
In the evaluation of the physiological responses after a
double-blind placebo/L-carnitine crossover design in
patients with MM, we observed that L-carnitine (3 g/day)
improved aerobic capacity and exercise tolerance during
a high-intensity constant-work exercise in a select group
of MM patients with CPEO.
Clinical characteristics and resting pulmonary
function of patients with MM
As previously reported (21), our patients had lower
weight, height, and muscle mass compared to controls
and a significantly higher mean RV, RV to total lung
capacity ratio, and reduced MVV compared to controls.
These findings might be related to a restrictive ventilatory
pattern that is commonly observed in patients with
neuromuscular diseases (22).
In the peripheral muscle evaluation, our patients
exhibited significantly less muscle strength than controls,
suggesting that the reduction in peripheral muscle
strength might be related to alterations in oxidative
phosphorylation, which is the hallmark characteristic of
these patients (4,21,22). Our patients also showed
significantly lower maximum exercise capacity and peak:
VO2 compared to controls. Several studies evaluating
exercise tolerance in MM have demonstrated markedly
low
:
VO2 peak (23-27), reflecting impaired muscle
mitochondrial oxidative phosphorylation. The maximal
exercise capacity of MM subjects has been shown to
directly correlate with the degree of O2 extraction in the
impaired muscle, which enables the use of the systemic
arterial to venous O2 difference as a surrogate marker for
mitochondrial oxidative capacity (3,4).
Effect of L-carnitine supplementation on exercise
performance in patients with MM
After oral supplementation of 3 g of L-carnitine over a
2-month period, we observed a statistically significant
change in the patients’ body composition as evaluated by
their body mass index, FFM, and FFMI. To our knowl-
edge, no studies have correlated changes in body
composition with L-carnitine supplementation in patients
with MM. Chazot et al. administered L-carnitine to chronic
renal failure patients on dialysis and also found no
changes in the body composition after this period of
Table 1. Characteristics of patients with mitochondrial myopathy (MM) and healthy controls.
MM (n=12) Controls (n=10)
Age (years) 34.5 ± 11.2 29 ± 7.8
Gender (M/F) 8/4 6/4
Weight (kg) 53.1 ± 13.5* 71.4 ± 9.8
Height (m) 1.61 ± 0.83* 1.70 ± 0.64
FFM (kg) 42.0 ± 9.3* 52.5 ± 7.9
BMI (kg/m2) 20.6 ± 4.3* 24.5 ± 2.8
AMC (cm) 19.4 ± 4.4* 24.8 ± 4.7
FFMI (kg/m2) 15.6 ± 2.4* 18 ± 2.0
FVC (% pred) 89 ± 13* 96.2 ± 9.8
FEV1 (% pred) 87 ± 16 93 ± 10
FEV1/FVC (%) 80 ± 0.1 80 ± 0.8
RV (% pred) 120 ± 27* 91 ± 29
TLC (% pred) 90 ± 10 88 ± 8.0
RV/TLC (%) 33.5 ± 5.5* 24.7 ± 6.9
MVV (% pred) 89 ± 25.3 120 ± 47.6
Data are reported as means±SD. BMI: body mass index; AMC: arm muscle circumference; FFM: fat-free
mass; FFMI: fat-free mass index; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; RV:
residual volume; TLC: total lung capacity; MVV: maximal voluntary ventilation; % pred: percent of
predicted. * P,0.05, compared to control (unpaired t-test).
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supplementation, suggesting that L-carnitine did not
influence body weight by decreasing fat mass (28).
No differences in peripheral muscle strength after L-
carnitine or placebo administration were observed, a
finding that is in accordance with the results of a study in
uremic patients with muscular atrophy. After 24-week
treatment with L-carnitine (2 g at the end of hemodialysis
or twice daily in the dialysis solution), other studies
Table 2. Peripheral muscle evaluation of patients with mitochondrial myopathy (MM) and healthy controls.
MM (n=12) Controls (n=10)
Peripheral muscle strength
PT (606/s; N/m) 93.4 ± 35.5* 150.2 ± 43.9
PT (% pred) 57.3 ± 15.9* 78.6 ± 16.8
IT (606/s) 113.6 ± 42.8* 157.6 ± 51.9
TW (3006/s; J) 720.1 ± 336.0+ 1577.5 ± 450.0
Data are reported as means±SD. PT: peak torque; N/m: Newton/meter; IT: isometric torque; TW: total
work; J: Joule; % pred: percent predicted. * P,0.05, +P,0.001, compared to control (unpaired t-test).
Table 3. Exercise responses of the patients with mitochondrial myopathy (MM) and the healthy controls
during peak cycling exercise.
MM (n=12) Controls (n=10)
Metabolic
Work rate (Watts) 88 ± 28+ 177 ± 38
:
VO2 (mL/min)
1193 ± 371+ 2155 ± 480
:
VO2 (% pred)
64+ 95
:
VO2AT (mL/min)
704 ± 273* 1013 ± 261
GER 1.19 ± 0.1 1.20 ± 0.08
Ventilatory
:
VE (% pred) 47.4 ± 14.3
+ 81.6 ± 20.9
f (ipm) 28.8 ± 8.5 42.2 ± 11.7
Vt (mL) 1372 ± 357+ 1991 ± 404.2
:
VE/
:
VCO2
30 ± 4.85 31 ± 5.18
:
VE/
:
VO2
35.7 ± 7.5 38.1 ± 6.0
:
VE/MVV 0.38 ± 0.1* 0.57 ± 0.15
PETCO2 (mmHg) 36.4 ± 5.5 37 ± 5.73
PETO2 (mmHg) 101.1 ± 6.7 103.7 ± 4.27
Cardiovascular
HRmax (bpm) 159 ± 18* 177 ± 8
HR (% pred) 86 ± 8* 95 ± 4
:
VO2/HR (mL/beat)
7.5 ± 2.8* 11.4 ± 3.2
:
VO2/HR (% pred)
77* 97
Symptoms
Borg dyspnea 5 3
Borg dyspnea/VE 0.111* 0.045
Borg LL 7 8
Borg LL/WR 0.096* 0.044
Data are reported as means±SD.
:
VO2: oxygen consumption; AT: anaerobic threshold; GER: gas-
exchange ratio;
:
VE: minute ventilation; f: respiratory frequency; Vt: tidal volume;
:
VCO2: CO2 output; MVV:
maximal voluntary ventilation; PETCO2: end-tidal PCO2; PETO2: end-tidal PO2; HR: heart rate; LL: lower
limbs; WR: work rate; % pred: percent predicted. * P,0.05, +P,0.001, compared to control (unpaired t-
test).
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reported an approximately 7% increase in the diameters
of type I and type IIa fibers, but no marked changes in
type IIb fibers (29-31). These findings suggest a specific
effect of L-carnitine on oxidative metabolism without
causing muscle hypertrophy (31,32).
In our study, we observed a higher
:
VO2 at Tlim and
isotime during constant work exercise, and these findings
were associated with significantly lower gas-exchange
ratio values. This result supports our hypothesis that L-
carnitine supplementation increases muscle oxidative
activity in patients with MM. Similarly, Gorostiaga et al.
(33) demonstrated that endurance athletes supplemented
with a daily dose of 2 g of L-carnitine for 28 days had
significantly lower values for gas-exchange ratio during a
66% of maximal CWR exercise, on a cycloergometer.
They suggested that the lower gas-exchange ratio values
after L-carnitine were related to increased lipid utilization
by peripheral muscles during exercise (33). Our hypoth-
esis for the increase in the CWR at Tlim and the increase
of
:
VO2 at both isotime and Tlim is that L-carnitine
optimizes glucose utilization during high-intensity exer-
cise. Under these conditions, carnitine could remove the
Table 4. Anthropometry, lung function and peripheral muscle performance of mitochondrial myopathy
patients, after L-carnitine or placebo supplementation.
L-carnitine Placebo
Anthropometry and lung volumes
BMI (kg/m2) 20.4 ± 1.1 20.6 ± 4.3
FFM (kg) 41.5 ± 2.8 42 ± 9.3
FFMI (kg/m2) 15.4 ± 0.7 15.6 ± 2.4
AMC (cm) 20.3 ± 0.9 19.4 ± 4.4
IC (L) 2.45 ± 0.23* 2.26 ± 0.22
IC (% pred) 87 ± 6.92* 83.5 ± 6.40
Peripheral muscle tests
PT (606/s; N/m) 95.4 ± 12.1 93.4 ± 35.5
IT (606/s) 115.5 ± 11.5 113.6 ± 42.8
TW (3006/s; J) 685.8 ± 367.4 720.1 ± 336
Data are reported as means±SD. BMI: body mass index; FFM: fat-free mass; FFMI: fat-free mass index;
AMC: arm muscle circumference; IC: inspiratory capacity; PT: peak torque; N/m: Newton/meter; IT:
isometric torque; s: second; TW: total work; J: Joule; % pred: % predicted. * P,0.05, compared to placebo
(unpaired t-test).
Table 5. Exercise responses of the patients with mitochondrial myopathy during the incremental
cardiopulmonary exercise test, after L-carnitine or placebo supplementation at peak exercise.
Peak L-carnitine Placebo
Metabolic
Work rate (watts) 90.5 ± 9.4 88.0 ± 28.1
:
VO2 (mL/min)
1216.7 ± 402 1193 ± 371
Lactate (peak) (mM) 6.4 ± 3.0 5.7 ± 1.5
Lactate (recovery) (mM) 7.8 ± 3.3 8.7 ± 3.5
Ventilatory
:
VE (% pred) 50.4 ± 15.0 47.4 ± 14.3
Cardiovascular
HR (bpm) 160 ± 19 159 ± 18
:
VO2/HR (mL/beat)
7.5 ± 2.6 7.5 ± 2.8
Symptoms
Borg dyspnea 4 5
Borg lower limbs 7 7
Data are reported as means±SD.
:
VO2: oxygen consumption;
:
VE: minute ventilation; HR: heart rate;
ICPET: incremental cardiopulmonary exercise test; peak: peak exercise in the ICPET; % pred: %
predicted. There were no significant differences between groups (P.0.05, unpaired t-test).
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excess acetyl groups that are formed during increased
pyruvate oxidation, which predominantly occurs in type I
muscle fibers. These effects maintain tricarboxylic acid
cycle reactions and increase oxidative metabolism (34-
36), which translated into an increased Tlim in our
patients. In addition, high-intensity exercise, both in
normal and MM subjects, has been found to reduce
muscle carnitine concentration by two mechanisms: i) the
high rate of acylcarnitine formation (7,36) and ii) increased
metabolic oxidation of fatty acids (7). Indeed, up to an
85% reduction in muscle carnitine levels has been
reported in patients with MM (7,37). Other studies have
shown that in diseases with a primary or secondary
carnitine deficiency, fatty acid oxidation occurs normally at
rest but dramatically declines during prolonged exercise
(cycloergometry) (34).
In conclusion, our findings suggest that at a higher
rate of fatty acid utilization, L-carnitine supplementation
was associated with a reduction in glucose metabolism,
thus preserving glycogen content and ensuring maximum
adenosine triphosphate oxidation rates. This was asso-
ciated with fatigue reduction and improved exercise
performance (7,37).
Study limitations
The results of this study should only be applied to
patients with MM and with CPEO who are without
evidence of cardiovascular manifestations or a more
severe form of the disease. In this regard, our patients
were selected on the basis of a histopathological and
clinical evaluation; their genotypic changes were not
considered. We did not measure their plasma or muscle
levels of carnitine, so we do not know whether these
patients actually had a carnitine deficiency and/or how
carnitine was retained in their muscles after supplementa-
tion. Another limitation was the small number of studied
patients. However, they had all presented exclusively with
CPEO at the Neuromuscular Diseases Clinic, Unifesp.
However, in a post hoc analysis, this sample size resulted
in significant power (.80%) for the principal variable
(Tlim) considered in this study (38).
Our results indicated that in patients with MM (CPEO
form), a 2-month program of L-carnitine supplementation
(3 g/day) led to an improvement in aerobic performance
characterized by: i) longer Tlim during a high-intensity
constant-work exercise and ii) increased O2 consumption
measured at Tlim and isotime.
The influence of L-carnitine on oxidative metabolism in
selected patients with MM provides insight into the
regulation of skeletal muscle fat and carbohydrate
oxidation during exercise. We suggest that these effects
should be tested in future studies of patients with chronic
and slowly-progressive muscle diseases such as MM.
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Table 6. Metabolic, ventilatory and cardiovascular exercise variables at constant work rate (CWR)
exercise at isotime and limit of tolerance (Tlim) in mitochondrial myopathy patients after L-carnitine or
placebo supplementation.
CWR L-carnitine Placebo
Isotime
:
VO2 (mL/min)
1151 ± 115* 1049 ± 104
GER 1.03 ± 0.04* 1.11 ± 0.04
:
VE (L/min) 45 ± 4 45 ± 4
HR (bpm) 157 ± 5 161 ± 4
:
VO2/HR (mL/beat)
7.4 ± 0.7 6.8 ± 0.6
Limit of tolerance
Tlim (min) 14 ± 1.9* 11 ± 1.4
:
VO2 at Tlim (mL/min)
1223 ± 114* 1060 ± 108
GER 1.4 ± 0.01 1.17 ± 0.03
:
VE (L/min) 48.4 ± 13 47.8 ± 14
HR (bpm) 159 ± 18 163 ± 17
:
VO2/HR (mL/beat)
7.7 ± 2.4* 7 ± 2.2
Data are reported as means±SD.
:
VO2: oxygen consumption; isotime: 6th min of exercise; Tlim: time limit
of tolerance in the CWR exercise; GER: gas-exchange ratio;
:
VE: minute ventilation; HR: heart rate.
* P,0.05, compared to placebo (unpaired t-test)
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